Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nelotanserin (APD125) 是5-HT2A 强完全逆向激动剂,5-HT2C 中等强度的部分反向激动剂和5-HT2B 的弱反向激动剂,IC50s 值分别为 1.7、79 和 791 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 491 | 现货 | ||
2 mg | ¥ 728 | 现货 | ||
5 mg | ¥ 1,230 | 现货 | ||
10 mg | ¥ 1,980 | 现货 | ||
25 mg | ¥ 3,730 | 现货 | ||
50 mg | ¥ 5,420 | 现货 | ||
100 mg | ¥ 7,590 | 现货 | ||
500 mg | ¥ 15,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,190 | 现货 |
产品描述 | Nelotanserin (APD125) is a potent 5-HT2A inverse agonist(IC50 : 1.7 nM), a moderately potent 5-HT2C partial inverse agonist t(IC50 :79 nM )and a weak 5-HT2B inverse agonistt(IC50 : 791 nM). |
靶点活性 | 5-HT2C receptor:79 nM , 5-HT2A receptor:1.7 nM , 5-HT2B receptor:791 nM |
体内活性 | In healthy human volunteers, nelotanserin was rapidly absorbed after oral administration and achieved maximum concentrations 1 h later. EEG effects occurred within 2 to 4 h after dosing, and were consistent with vigilance-lowering. A dose response of nelotanserin was assessed in a postnap insomnia model in healthy subjects. All doses (up to 40 mg) of nelotanserin significantly improved measures of sleep consolidation, including decreases in the number of stage shifts, number of awakenings after sleep onset, microarousal index, and number of sleep bouts, concomitant with increases in sleep bout duration. Nelotanserin did not affect total sleep time, or sleep onset latency. Furthermore, subjective pharmacodynamic effects observed the morning after dosing were minimal and had no functional consequences on psychomotor skills or memory[1]. |
别名 | 1-[3-(4-溴-1-甲基-1H-吡唑-5-基)-4-甲氧基苯基]-3-(2,4-二氟苯基)脲, APD125 |
分子量 | 437.24 |
分子式 | C18H15BrF2N4O2 |
CAS No. | 839713-36-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 32 mg/mL (73.19 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2871 mL | 11.4354 mL | 22.8707 mL | 57.1768 mL |
5 mM | 0.4574 mL | 2.2871 mL | 4.5741 mL | 11.4354 mL | |
10 mM | 0.2287 mL | 1.1435 mL | 2.2871 mL | 5.7177 mL | |
20 mM | 0.1144 mL | 0.5718 mL | 1.1435 mL | 2.8588 mL | |
50 mM | 0.0457 mL | 0.2287 mL | 0.4574 mL | 1.1435 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Nelotanserin 839713-36-9 GPCR/G Protein Neuroscience 5-HT Receptor 1-[3-(4-溴-1-甲基-1H-吡唑-5-基)-4-甲氧基苯基]-3-(2,4-二氟苯基)脲 Inhibitor inhibit APD125 APD-125 APD 125 Serotonin Receptor 5-hydroxytryptamine Receptor inhibitor